Physicochemical profiling of nanomedicines using centrifugal field flow fractionation

Int J Pharm. 2024 Sep 30:663:124571. doi: 10.1016/j.ijpharm.2024.124571. Epub 2024 Aug 10.

Abstract

Nanomedicines comprise multiple components, and particle density is considered an important property that regulates the biodistribution of administered nanomedicines. The density of nanoparticles is characterized by centrifugal methods, such as analytical ultracentrifugation. Particle size and distribution are key physicochemical and quality attributes of nanomedicines. In this study, we developed a novel profiling method applicable to liposomes and lipid nanoparticles (LNPs), based on particle size and density, using centrifugal field-flow fractionation (CF3). We evaluated the elution profiles of PEGylated liposomes of different sizes with various doxorubicin (DOX)-loading amounts using CF3. This method was applied to evaluate the drug release of DOX-loaded liposomes, intra- and inter-batch variability, reconstitution reproducibility of AmBisome®, and elution characteristics of LNPs in COVID-19 vaccines (Comirnaty® and SpikevaxTM). The data obtained in the present study underscore the significance of the proposed methodology and highlight the importance of profiling and characterizing liposomes and LNPs using CF3 fractograms and a multi-angle light-scattering detector.

Keywords: Field flow fractionation; Nanomedicine; Nanoparticle density; Particle size; Profiling.

MeSH terms

  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / chemistry
  • Centrifugation / methods
  • Doxorubicin* / administration & dosage
  • Doxorubicin* / analogs & derivatives
  • Doxorubicin* / chemistry
  • Doxorubicin* / pharmacokinetics
  • Drug Liberation
  • Fractionation, Field Flow* / methods
  • Liposomes*
  • Nanomedicine* / methods
  • Nanoparticles* / chemistry
  • Particle Size*
  • Polyethylene Glycols* / chemistry
  • Reproducibility of Results

Substances

  • Liposomes
  • Doxorubicin
  • Polyethylene Glycols
  • liposomal doxorubicin
  • COVID-19 Vaccines
  • Lipid Nanoparticles